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Objectives. An initial crossover study comparing dual- and
single-site right atrial pacing was performed followed by a long-
term efficacy and safety evaluation of dual-site right atrial pacing
in patients with drug-refractory atrial fibrillation (AF). Also
examined was the efficacy of two single-site right atrial pacing
modes (high right atrium and coronary sinus ostium) and the
long-term need for cardioversion, antithrombotic and antiar-
rhythmic drug therapies during dual-site atrial pacing.
Methods. Thirty consecutive patients with drug-refractory
symptomatic AF and documented primary or drug-induced bra-
dycardia were implanted with a dual chamber rate-responsive
pacemaker and two atrial leads. Single-site atrial pacing was
performed at the high right atrium or the coronary sinus ostium.
Continuous atrial pacing was maintained.
Results. Mean arrhythmia-free intervals increased from 9 6 10
days in the control period preceding implant to 143 6 110 days
(p < 0.0001) in single-site right atrial pacing and 195 6 96 days
in dual-site right atrial pacing (p < 0.005 versus single-site pacing
and p < 0.0001 versus control). Dual-site right atrial pacing
significantly increased the proportion of patients free of AF
recurrence (89%) as compared to single-site right atrial pacing
(62%, p 5 0.02). High right atrial pacing and coronary sinus ostial
pacing had similar efficacy for AF prevention. Effective rhythm
control was achieved in 86% of patients during dual right atrial
pacing. Seventy-eight percent of patients at 1 year and 56% at 3
years remained free of symptomatic AF. The need for cardiover-
sion was reduced after pacemaker implant (p < 0.05) and
antithrombotic therapy was reduced (p < 0.06) without any
thromboembolic event. Coronary sinus ostial lead dislodgement
was not observed after discharge.
Conclusions. Atrial pacing in combination with antiarrhythmic
drugs eliminates or markedly reduces recurrent AF. Prevention of
AF is enhanced by dual-site right atrial pacing. High right atrial
and coronary sinus ostial pacing do not differ in efficacy. Dual-site
right atrial pacing is safe, achieves long-term rhythm control in
most patients, decreases the need for cardioversion, and anti-
thrombotic therapy can be selectively reduced.
(J Am Coll Cardiol 1998;32:1900–8)
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Prevention of atrial fibrillation (AF) has become a major
therapeutic challenge with increasing knowledge of the mor-
bidity and mortality related to this widely prevalent arrhythmia
(1). Numerous studies (2–4) have shown incomplete or even
ineffective rhythm control with antiarrhythmic drug therapy
when used alone for AF prevention. Currently, new non-
pharmacologic methods such as multisite atrial pacing, cathe-
ter ablation, and direct atrial surgery are under active devel-
opment for treatment of drug-refractory patients with AF.
Atrial pacing has been shown to reduce AF recurrence rates as
compared to ventricular pacing in retrospective (5–7) and
prospective studies (8,9). Recently, it has been suggested that
methods such as dual-site right atrial pacing (10) and biatrial
resynchronization (11) have an incremental benefit relative to
both high right atrial pacing and antiarrhythmic drug therapies
on short-term follow-up. Acute electrophysiologic studies (12)
have suggested that reduction in atrial conduction delay and
modification of dispersion in atrial refractoriness are impor-
tant mechanisms of improved AF prevention by multisite atrial
pacing. Single-site atrial pacing may also be of value in
arrhythmia prevention (10). The optimal pacing site for single-
site pacing is still unknown, but lately, coronary sinus locations
have been advocated (13). With the known proarrhythmic risk
of some antiarrhythmic agents, the safety of such combination
therapy is also unclear (2,14–16).
The long-term results of dual-site right atrial pacing in
patients with drug-refractory AF have not been reported.
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Effective long-term AF prevention has important implications
for antithrombotic therapy, antiarrhythmic drug and cardiover-
sion therapies in this arrhythmia. In this article, the long-term
results of a prospective study employing atrial pacing for AF
prevention is reported. Firstly, a sequential crossover design
was used to compare the efficacy of dual-site right atrial pacing
with single-site right atrial pacing in patients with drug-
refractory AF. Secondly, we also evaluated the efficacy of two
single-site right atrial pacing methods, namely high right atrial
pacing and coronary sinus ostial pacing to address the possi-
bility of an optimal single right atrial pacing site. Finally, we
examined the feasibility of long-term rhythm control with
dual-site right atrial pacing after the completion of the cross-
over phases to address the need for continued antithrombotic
therapy, antiarrhythmic and cardioversion therapies with this
pacing mode.
Methods
Pacemaker implantation. The patient selection, study pro-
tocol, methods of implantation, and pacing system for our pilot
study have been previously described in detail elsewhere (10).
Briefly, in consecutive consenting patients with drug-refractory
symptomatic AF or flutter and a documented primary or
drug-induced bradycardia, we implanted a DDDR pacemaker
generator (Medtronic Elite 7086 or Thera 7960i dual chamber
rate responsive pacemaker, Medtronic Inc., Minneapolis, Min-
nesota) with dual atrial leads (Medtronic models 4568-53 and
4068-58) and a right ventricular lead (Medtronic model 5034-
58). The two pacing leads were fixed in the right atrium, one at
the high right atrium and the other just outside the coronary
sinus ostium. An active screw-in fixation lead was invariably
used at the coronary sinus ostium. The atrial leads were
connected via a Y-connector to the atrial output of the
pacemaker. The cathode was the high right atrial lead in the
first 16 patients and the coronary sinus ostium lead in the next
14 patients. The ventricular lead was positioned at the right
ventricular apex and connected to the ventricular output of the
pacemaker. The pacemaker was programmed in the DDDR
mode with a lower rate between 80–90 bpm; an individual rate
response and the sensor threshold was selected to obtain
continuous overdrive atrial pacing. Unipolar atrial pacing
allowed single-site right atrial pacing from the cathodal lead
only and bipolar atrial pacing established dual-site right atrial
pacing from both cathodal and anodal electrodes with a
biphasic P wave morphology in leads II, III, and aVF. The
atrial sensing threshold was usually set at 0.5 mV. At the time
of an atrial high rate event detection (.175 bpm), the atrial
electrogram intervals were stored in the pacemaker memory
up to a maximum of eight consecutive events. The pacemaker
datalogs also stored atrial electrograms for one recorded event.
Paced and sensed events were categorized continuously in
device memory and also for the stored events. The percentage
of atrial pacing was perioperatively reviewed to ensure that the
objective of continuous atrial pacing was achieved. Continuous
atrial overdrive pacing was considered acceptable if the per-
centage of paced atrial events was .80% of all atrial events. If
this percentage of atrial pacing was not reached, the pace-
maker was reprogrammed with a more aggressive atrial pacing
prescription and/or the drug regimen was modified by either
increasing the dose or changing the drug.
Study protocol and follow-up. The study protocol consisted
of an initial prospective sequential crossover comparison of
dual-site right atrial pacing and single-site right atrial pacing
efficacy in prevention of AF. The patients were successively
paced in these two modes initially for 90-day periods and then
180-day periods or if a symptomatic AF recurrence was noted
(Fig. 1). At the crossover study completion, the patients’
pacemakers were definitively reprogrammed to the dual-site
right atrial pacing mode to study long-term rhythm control.
During follow-up, all patients were followed with periodic
clinic visits, accompanied by electrocardiogram (ECG) record-
ings, at intervals of three months or less with their cardiologist
and/or their primary physician. Pacemaker clinic visits were
scheduled at 1 week postoperatively, 1 month, 3 months, and
then at 3-month intervals. ECGs and interrogation of the
pacemaker datalogs were performed at each clinic visit.
Twenty-four hour ambulatory ECG recordings were per-
formed at 1 month and 4 months if the patient had symptoms
potentially suggestive of arrhythmia recurrence, and also be-
fore antiarrhythmic drug and antithrombotic treatment with-
Abbreviations and Acronyms
AF 5 atrial fibrillation
CI 5 confidence interval
ECG 5 electrocardiogram/electrocardiographic
Figure 1. Schematic diagram summarizing the pilot and
long-term study protocols. The pilot study protocol used
a sequential crossover study design and included two
pacing groups for single-site pacing. The initial group of
16 AF patients paced were from the high right atrium in
the single-site mode and a subsequent group of 14 AF
patients were paced from the coronary sinus ostium in
the single-site mode. At the pilot study completion, all
patients were switched to the dual-site right atrial pacing
mode and followed long-term. CSos 5 coronary sinus
ostium; DAP 5 dual-site right atrial pacing; HRA 5
high right atrium.
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drawal. Transtelephonic and event monitoring were also per-
formed in symptomatic patients who also subsequently
underwent a 12-lead and an ambulatory ECG.
After pacemaker implantation, all patients were usually
placed on a previously ineffective antiarrhythmic drug treat-
ment. The daily drug dose was reduced or the antiarrhythmic
drug treatment was withdrawn if the patient had no arrhythmia
recurrence for a minimum period of one year. Antithrombotic
treatment was instituted in accordance with previously estab-
lished guidelines (17). The choice of warfarin or aspirin was
based on age, associated risk factors, and the presence or
absence of contraindications to each therapy. Antithrombotic
treatment was withheld in patients with contraindications to
this therapy. If no asymptomatic or symptomatic AF episode
was documented for a period of one year as determined from
pacemaker data logs, periodic Holter monitoring, clinic visits
and event recordings in symptomatic patients, antithrombotic
treatment therapy was evaluated for potential withdrawal.
Statistical analysis. Continuous variables are expressed as
mean 6 SD and were compared by two-tailed paired or the
unpaired Student t test. Subgroup comparison of categorical
variables were performed using Fisher’s exact test. The actu-
arial graphs of the primary endpoints, i.e., arrhythmia-free
intervals, and time to first and subsequent AF recurrence are
presented using the Kaplan-Meier life table method for actu-
arial analysis. For purposes of analysis of arrhythmia-free
intervals in single- and dual-site right atrial pacing during the
sequential crossover study periods, the two segments in each of
two pacing modes were combined for a maximal arrhythmia-
free interval of 270 days. The discontinuous nature of the two
time periods is eliminated in the actuarial analysis. The Log
Rank test was also applied for comparison of these curves. For
all comparisons, the difference was considered significant at a
level of 5%.
Results
Patient population. Thirty patients (14 men and 16
women) with a mean age of 69 6 12 years were enrolled in the
study and followed up for 28 6 11 months (range 0–41). All
patients had recurrent, refractory and symptomatic AF or
atrial flutter of 42 6 50 months duration with a documented
bradycardia (#45 bpm). The primary indication for cardiac
pacing was sick sinus syndrome in 8 (27%) patients, conduction
system disease in 6 (20%), drug-induced bradycardia
(#45 bpm) in 11 (37%) and neurocardiogenic syncope with a
bradycardic mechanism in 5 (17%) patients; thus, 16 of 30
(53%) patients lacked a primary persistent bradycardia, coex-
isting at the time of appearance of spontaneous AF or atrial
flutter. Spontaneous AF episodes when documented also
confirmed the absence of a preceding bradycardia in these
patients.
Twenty-six patients had AF. It was paroxysmal in 21 and
chronic in 5. Six of these AF patients also had associated
paroxysmal atrial flutter. Three study patients had paroxysmal
atrial flutter alone and one patient had a combination of
paroxysmal atrial flutter and atrial tachycardia. Their mean left
atrial diameter was 39 6 7 mm and mean left ventricular
ejection fraction was 46 6 11%. Twenty-two (73%) patients
presented with cardiovascular disease, 12 patients had coro-
nary artery disease, 5 patients had hypertensive heart disease,
2 patients had dilated cardiomyopathy, 1 patient had valvular
heart disease, 1 patient had hypertrophic cardiomyopathy and
1 patient had congenital heart disease. Before pacemaker
system implantation, pharmacologic treatment of AF had
failed to prevent AF or flutter in all patients with a mean of
3.6 6 1.7 antiarrhythmic drugs. Five patients have failed
preceding attempts of atrial flutter and atrial tachycardia
ablation. One patient withdrew from the study immediately
after pacemaker implantation due to severe heart failure and
entered a cardiac transplant program. This patient was cen-
sored from the analysis at that point. Four patients declined
crossover to single-site atrial pacing after institution of dual-
site right atrial pacing during the course of the study.
Efficacy of atrial pacing in AF prevention during crossover
trial. Fig. 2 shows the percent freedom from any AF or flutter
recurrences in the study population in the three-month period
before institution of pacing (the control period on antiarrhyth-
mic drug therapy alone) and after institution of atrial pacing
for both pacing modes during the entire duration of the pilot
crossover study. Before pacing, all patients had experienced
very frequent AF with at least two relapses within the prior 90
days. No patient was AF eventfree after 41 days in the control
period. In the single-site right atrial pacing mode, 62% of
patients were free of AF recurrence during nine months of
combined follow-up in study phases 2 and 4 (p , 0.0001 versus
control). Dual-site right atrial pacing significantly increased the
proportion of patients free of AF recurrence in a similar
Figure 2. Actuarial curves show the percentage of patients free of AF
recurrence before pacemaker implant, and during the period of the
pilot crossover study (270 days each in single- and dual-site pacing).
Atrial pacing significantly improves the proportion of patients free of
AF recurrence as compared to before pacemaker implant. In the
dual-site right atrial pacing mode, there is significant additional benefit
as compared to single-site atrial pacing. Both single-site atrial pacing
modes are combined for this analysis. AF 5 atrial fibrillation; DAP 5
dual-site right atrial pacing; pts 5 patients; SAP 5 single-site atrial
pacing.
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follow-up in combined phases 1 and 3 to 89% (p 5 0.02 versus
single-site right atrial pacing and p , 0.0001 versus control).
The mean arrhythmia-free interval (Fig. 3) for the entire study
population was 9 6 10 days (range 1–41 days) before pacing
and increased significantly to 143 6 110 days (range 1–270
days) in single-site right atrial pacing (p , 0.0001) and to
195 6 96 days (range 25–270 days) in dual-site right atrial
pacing (p , 0.005 versus single-site right atrial pacing and p ,
0.0001 versus control). Four patients died during the course of
the pilot crossover study (renal failure in 2 patients, malig-
nancy in 1 patient, and respiratory failure in 1 patient).
Ten of 25 (40%) patients had one or more AF recurrences
in single-site right atrial pacing. Five of 29 (17%) patients had
AF recurrences in dual-site right atrial pacing (p 5 0.06 versus
single-site pacing) and all 4 patients who crossed over also had
a recurrence in single-site right pacing. Three patients with
paroxysmal AF and one patient with chronic AF lost rhythm
control in phase 3 of the crossover study. In one patient, this
was due to withdrawal of all antiarrhythmic drugs due to
multiple drug intolerance. These four patients remained in
chronic AF subsequently.
The relative risk for AF recurrences compared to the
control period was significantly lower during dual-site right
atrial pacing (0.05, 95% confidence interval [CI] 0.02–0.09),
and single-site atrial pacing (0.16, 95% CI 0.05–0.20). Com-
paring dual- to single-site atrial pacing, the relative risk of AF
recurrence was significantly lower (0.25, 95% CI 0.08–0.80).
Efficacy of individual right atrial pacing sites during single-
site pacing in the crossover study. Both coronary sinus ostial
pacing and high right atrial pacing (Fig. 4) significantly in-
creased the proportion of patients free of AF recurrences at
nine months when compared to the control period (53%, 71%
versus 0% respectively, p , 0.0001). There was no significant
difference in efficacy in AF prevention between coronary sinus
ostial pacing and high right atrial pacing (p 5 0.36). The mean
arrhythmia-free interval (Fig. 5) compared to the control
period was also significantly increased by coronary sinus ostial
pacing (145 6 125 days versus 5 6 2 days) and high right atrial
pacing as compared to the control period (142 6 102 days
versus 14 6 13 days, p , 0.001). The mean arrhythmia-free
interval was not significantly different between high right atrial
and coronary sinus ostial pacing (p 5 0.94). Five of 16 patients
had a recurrence of AF in high right atrial pacing and 5 of the
14 remaining patients had recurrent AF in coronary sinus
ostial pacing.
Comparing high right atrial to coronary sinus ostial pacing,
the relative risk was not significantly lower (0.55, 95% CI
0.13–2.05); however, coronary sinus ostial pacing had signifi-
cantly lower risk of AF recurrence compared to the control
period (0.25, 95% CI 0.05–0.42) as did high right atrial pacing
(0.11, 95% CI 0.02–0.18).
Long-term rhythm control during dual-site right atrial
pacing. After the initial crossover study period which ex-
tended from 6 to 18 months, the follow-up during dual-site
right atrial pacing in 21 remaining patients has ranged from 25
up to 41 months. Fourteen (67%) patients did not experience
any recurrent AF during dual-site right atrial pacing in the
long-term study period. One of the seven patients with AF
recurrence had been without AF for 3.5 years and did have a
recurrence due to loss of atrial pacing at pacemaker generator
end-of-life when the device reverted to demand ventricular
Figure 3. Mean arrhythmia-free in days before pacemaker implant, in
dual-site right atrial pacing, and in single-site right atrial pacing. There
is a significant increase in this parameter with any form of atrial pacing
with an additional significant gain with dual-site right atrial pacing.
DAP 5 dual-site right atrial pacing; SAP 5 single-site atrial pacing.
Figure 4. Freedom from recurrent AF before and after
pacemaker system implant in patients undergoing high
right atrial pacing and coronary sinus ostial pacing using
Kaplan-Meier analysis. Both single-site atrial pacing
modes significantly improve the proportion of patients
without recurrent AF as compared to before pacing;
however, there is no significant difference between HRA
pacing and CSos pacing. AF 5 atrial fibrillation; CSos 5
coronary sinus ostial; HRA 5 high right atrial; pts 5
patients.
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pacing. Rhythm control or return to atrial paced rhythm was
reestablished after reinstitution of dual-site pacing and drug
therapy. All six remaining patients have had only one AF
recurrence which was due to drug withdrawal secondary to
intolerance in one patient. The overall mean arrhythmia-free
interval for the study population at last follow-up was 513 6
360 days.
Arrhythmia control in combined crossover and long-term
study. Fig. 6 shows the actuarial freedom from AF recurrence
and rhythm control achieved up to 3.5 years of follow-up in the
two segments of our study. The proportion of patients remain-
ing free of AF recurrence was 78% at 1 year, 63% at 2 years,
and 56% at 3 years. Four (13%) patients progressed to or
remained in chronic AF. At last follow-up, 25 of 29 patients in
whom a paced rhythm could be established remained atrially
paced. Atrial pacing could not be initially established for any
significant period in the one (3%) remaining patient due to
intractable heart failure and severe mitral regurgitation. This
patient was referred to a heart transplant program and cen-
sored from the study. The presence or absence of symptomatic
primary bradycardia in this patient population did not influ-
ence the ability to achieve rhythm control (p 5 0.13); however,
the extent of arrhythmia-free intervals was significantly greater
(p , 0.02) in patients with primary bradycardia (.1,000 days)
than in those without it (p , 0.05).
Pattern of recurrence of AF during combined single- and
dual-atrial pacing. The time course and frequency of AF
recurrences in patients demonstrating recurrent symptomatic
AF events is shown in Fig. 7. There is an increased event rate
(0.77 events/patient over a six-month interval) during the first
six months. The event rate in phase 1 (dual-site right atrial
pacing) was 0.23 and in phase 2 (single-site right atrial pacing)
was 0.54. This observed rate was thus in part potentially
attributable to the crossover into phase 2 (high right atrial
pacing) since subsequently a much lower rate of events (0.3
events/patient) was observed in the subsequent six-month
periods which were predominantly in dual-site right atrial
pacing. In this regard, no further change in frequency is
obvious after the initial six months.
The potential etiologies for recurrent AF in both pacing
modes was analyzed. Of a total of 13 symptomatic and/or
self-terminating AF recurrences observed in the seven patients
during the pilot and long-term dual-site right atrial pacing
phases, seven were related to either antiarrhythmic drug
treatment modification (2 recurrences), heart failure (2 recur-
rences), pneumonia (1 recurrence), loss of atrial pacing (1
recurrence), or combination of heart failure and drug modifi-
cation (1 patient). No causative or precipitating factor could be
identified for the remaining six recurrences. During the two
pilot phases of single-site right atrial pacing, 10 recurrences
occurred in 10 patients. Two (20%) recurrences were attrib-
uted to a drug withdrawal (intolerance) and drug dose reduc-
tion of drug (intolerance). No etiology nor precipitating factor
could be documented for the eight (80%) other recurrences.
Long-term single-site pacing was not performed by study
design.
Antiarrhythmic drug treatment. Fig. 8 shows the distribu-
tion of antiarrhythmic drugs given to the patients immediately
after implant and at last follow-up. There was a decrease in
class 1 drug use because of intolerance (two patients) or
inefficacy (five patients). One additional patient continues on a
class 1 drug at last follow-up after being switched from a class
3 drug for drug intolerance. The number of patients initially
and finally treated with class 3 drugs remained equal; however,
out of the nine patients initially on class 3 drugs, only four
patients remained on the same drug and dosage. This treat-
Figure 5. Mean time interval to first AF recurrence in days before
pacemaker implant, during high right atrial pacing and coronary sinus
ostial pacing in the pilot crossover study. There is a significant benefit
with both atrial pacing modes as compared to the period before pacing
was instituted, but no significant difference in this parameter between
these two pacing sites. CSos 5 coronary sinus ostial; HRA 5 high right
atrial.
Figure 6. Percentage of patients achieving rhythm control and those
free of any AF events (arrhythmia-free) after institution of dual-site
right atrial pacing. Fifty-six percent of patients were arrhythmia-free at
42 months of follow-up. Rhythm control (i.e., continuous atrial pacing)
could be achieved in 86% of patients at the same time interval. Four
patients went to chronic AF; three had had prior chronic AF. Pts 5
patients.
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ment was stopped in three patients, changed for another class
3 drug in one patient, and changed for a class 1 drug in one
patient. Four patients were switched over to a class 3 drug.
There was little overall change in class 2 and 4 drug use during
the entire period of treatment. In 14 patients, we employed a
combination of class 2 or 4 drugs with class 1 or 3 drugs at
implant; 9 patients continued on the combination at last
follow-up. The number of patients without any antiarrhythmic
drug treatment has increased slightly. At last follow-up, there
were five patients on no antiarrhythmic drug which included
four patients who were not commenced on a drug at pacing
system implant. The four patients initially untreated with drug
therapy did not experience any AF recurrence.
Cardioversion therapy after dual-site right atrial pacing.
Twenty-three (77%) patients in the study had cardioversion
performed prior to pacing system implant in the year preceding
pacemaker implant. The subsequent need for direct current
cardioversion over the course of the study period is shown in
Fig. 9. All symptomatic AF recurrences are also depicted. As
can be seen, often self-terminating AF recurrences were
observed. Patients required direct current or drug cardiover-
sion during the follow-up period. The overall need for cardio-
version is very modest and somewhat higher in the initial six
months paralleling the recurrent AF pattern, reflecting in part
the crossover to single-site pacing in phase 2. After six months,
a relatively low monthly event rate is noted reflecting the
infrequent recurrences in patients who exhibit this arrhythmia
after dual-site atrial pacing.
Antithrombotic treatment. During the study, there has
been no embolic event observed clinically nor evidence of any
cerebrovascular accidents. At implant, 23 (79%) patients were
on antithrombotic treatment. Fourteen were on warfarin and
nine on aspirin. Six (21%) patients were not on antithrombotic
therapy because of contraindications in three patients, non-
compliance in one patient, and complications (perioperative
hematomas) in two patients. These hematomas subsided with
Figure 8. Concomitant antiarrhythmic drug therapy with atrial pacing
in study patients immediately after device implant and at last follow-
up. There was a significant decrease in class 1 drugs use. (See text for
details).
Figure 7. Temporal distribution of AF recurrences
per patient in 6-month intervals after pacing system
implant in the 13 patients with recurrent AF during
the entire study period. The recurrence rate was
more frequent during the first six months especially
during the first phase of single-site atrial pacing.
Subsequently, the recurrence rate was lower and
did not change significantly from 7 to 42 months.
Figure 9. Need for direct current cardioversion after institution of
atrial pacing over the course of the study period. Spontaneous
conversions of recurrent AF are frequently seen during the entire
follow-up period. Cardioversions were more frequent during the first
six months which included crossover to the single-site atrial pacing
mode. After six months, a very low cardioversion rate is noted
reflecting the infrequent recurrences during dual-site atrial pacing
(0.2–0.3 events/pt semiannually).
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conservative management and did not require evacuation. At
last follow-up, there is a significant modification of the anti-
thrombotic treatment. Thirteen patients (45%) who had at
least one documented recurrence are still on antithrombotic
therapy. Antithrombotic therapy was not being employed in 16
(55%) patients with 10 patients having initially initiated ther-
apy being withdrawn. The mean time to withdrawal of anti-
thrombotic treatment was 19 6 13 months. As compared to
implant period, there is a significant reduction in antithrom-
botic treatment usage with dual-site right atrial pacing. War-
farin has been replaced by aspirin in two patients. Eleven
patients who had withdrawal of initially instituted antithrom-
botic therapy have been followed for 9–27 months. They have
remained without such therapy in ten patients while it has been
replaced with aspirin in one patient.
Complications. These were related to device implant.
There was a single intraoperative coronary sinus lead dislodge-
ment which was inadvertently located just inside the ostium
and was immediately repositioned outside the ostium. There
has been no lead dislodgement after hospital discharge. One
patient had a pneumothorax at implant requiring evacuation.
There were two late complications (pocket infection; pocket
twitch due to disruption of adhesive insulation of Y-connector)
which required system explant or revision.
Discussion
Single-site atrial pacing has been shown to be associated
with a reduced risk of recurrent AF in patients with sick sinus
syndrome with and without manifest AF (5–7). Recently
reported prospective studies in this population have confirmed
this observation (8,9). The ability of atrial pacing to prevent
AF recurrences has not been well understood nor has the
quantitative extent of benefit been characterized. Further-
more, whether this benefit is a direct effect on the atrial
arrhythmia or mediated by prevention of associated bradycar-
dia has been unclear. The extension of this benefit to popula-
tions with AF alone is also unknown. While we and others have
suggested increased benefit with dual-site atrial pacing, the
long-term efficacy and relative benefits of this new pacing
method vis-a-vis traditional single-site atrial pacing remain
undefined. Whether the efficacy of single-site atrial pacing can
be enhanced by new atrial pacing sites is also conjectural but
has been suggested (13). Finally, it is critical to know whether
this pacing preventative strategy could be combined with atrial
defibrillation in implantable devices, and reduce the need for
drug (antiarrhythmic or antithrombotic), cardioversion or de-
fibrillation therapy. Our prospective study with its initial
sequential crossover design between single- and dual-site right
atrial pacing and subsequent long-term outcome in dual-site
right atrial pacing provides insights and information relative to
all these issues. The use of two single atrial sites was performed
sequentially since the safety and efficacy of long-term coronary
sinus ostial pacing were unknown at the time of study com-
mencement.
AF prevention with atrial pacing. In our population with
very frequent recurrent AF with an average arrhythmia-free
interval of nine days, both single- and dual-site right atrial
pacing, most often in combination with antiarrhythmic drug
therapy, demonstrated clear benefit in prevention of recurrent
AF (14). Elimination or a marked reduction in recurrent AF
was achieved in 25 of 29 patients. In single-site right atrial
pacing, 62% of patients had elimination of recurrent AF
during a nine-month follow-up with a significantly higher
proportion (82%) being arrhythmia-free in dual-site right
atrial pacing. The remaining patients had a marked reduction
in recurrence rates with very infrequent events (1–3) over a
mean follow-up of .2 years. The mean arrhythmia-free inter-
val increased to 143 and 195 days, respectively, during a
follow-up period censored at 270 days. Clearly, with unlimited
follow-up, this would be significantly longer. This is apparent
during long-term follow-up with dual-site right atrial pacing
when the arrhythmia-free interval has increased to a mean
value of 513 6 360 days. This observation would argue that the
preventative benefits of dual-site right atrial pacing are long-
term in nature.
There is clear evidence from this study to suggest that there
is an incremental benefit in AF prevention with dual-site right
atrial pacing over the single-site pacing methods used in the
study. Five additional patients became arrhythmia-free in the
former mode and the mean arrhythmia-free interval increased
by 36% in the first nine months of follow-up alone. The former
translates into possible benefits with potential for reduction in
antiarrhythmic drug therapy and even antithrombotic therapy
while the latter would reduce the need for cardioversion
therapies. In patients with recurrent AF, the frequency of
recurrences and intervals between them also increased with
dual-site atrial pacing. Both single-site atrial pacing modes had
comparable efficacy, suggesting that an ideal individual site was
not present between these two choices. Biatrial pacing has also
been shown to be effective in prevention of atypical left atrial
flutter and AF (11). This has been thought to be due to similar
mechanisms as in our patients but uses a triggered pacing
algorithm.
The incidence of subsequent chronic AF in patients with
paroxysmal arrhythmia at study entry was 3 of 25 (12%)
patients during the study period up to 3.5 years for an annual
incidence of 5%. In prior reports of single-site atrial pacing in
patients with sick sinus syndrome and history of AF, the
estimated incidence was .20% annually (15). While the
populations are not exactly identical, these data do suggest
potential further benefit with dual-site pacing.
Patient selection for preventative dual-site right atrial
pacing. This benefit of atrial pacing in prevention of AF has
been seen in patients with and without manifest bradyarrhyth-
mias at the time of AF emergence. This would suggest that this
beneficial effect is a direct action on the atrial arrhythmia
rather than mediated by bradycardia prevention. In fact, we
have not documented a single episode of recurrent spontane-
ous AF before or after pacing which is preceded by bradycar-
dia. We would suggest that patients with recurrent paroxysmal
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or persistent AF can be candidates for this treatment modality.
Four of 5 patients with chronic AF achieved rhythm control;
further study is needed in this group. The presence of cardiac
disease was noted in most of our patients. Lone AF patients
were a relatively uncommon minority; thus, patients with
organic heart disease and AF are candidates for atrial pacing
therapies. Modest enlargement of the left atrium and de-
pressed left ventricular systolic function do not contraindicate
this procedure. Intractable heart failure or severe mitral
regurgitation have not been associated with AF suppression
and should be exclusions for patient selection at this time.
Patients with primary bradycardia achieved longer arrhythmia-
free intervals (.1,000 days) than those without it (p , 0.05).
Impact of atrial pacing on concomitant drug and electrical
therapies. Atrial pacing established rhythm control in 82% of
patients during this long-term study. Reduction in antiarrhyth-
mic drug therapy (particularly class 1 agents) was indeed
achieved in a significant minority (16%) of patients; however,
a major limitation was the need for drug therapy changes for
intolerance or inefficacy, most often to a class 3 drug. Our
current policy is now to start with such class 3 agents, especially
in view of the risk of ventricular proarrhythmia in patients with
coronary heart disease and left ventricular dysfunction (15).
Antithrombotic therapies could be eliminated in ten pa-
tients, fully 33% of the study group. This was in accordance
with clinical guidelines operative at the time of the study (17).
While the long-term (.5 years) impact of this reduction
cannot be judged from this study in terms of efficacy and safety,
the absence of embolic events in this study is hypothesis
generating for the future.
The need for cardioversion therapies in this population is
eliminated or markedly reduced based on the clinical course of
these patients. Seventy-seven percent of all patients had had
one or more cardioversion therapies in the year prior to the
implantation of the pacing system. Nineteen patients never
required cardioversion after system implant; however, only 13
patients had recurrent AF with 44% being self-terminating in
nature. Cardioversion was necessary in ten patients with three
patients requiring more than one (maximum three) cardiover-
sion. For patients with an average arrhythmia-free interval of
,10 days, this frequency over a course of several years is
remarkably low. Our data are compelling evidence that pre-
vention of AF by atrial pacing reduces the need for direct
current or other cardioversion therapy.
Role of atrial pacing in implantable atrial defibrillation
devices. Based on our data, a role for dual-site and single-site
right atrial pacing can be defined in a rhythm management
device. Prototype devices have lacked this capability and shock
frequency during follow-up has been variable (18). Dual- and
single-site atrial pacing can reduce the need for shock therapy
for cardioversion and defibrillation in such devices by reducing
the frequency of recurrent atrial flutter and AF. It could be
envisaged that such pacing therapies could be invariably pro-
grammed as a first line of treatment for prevention. Algorithms
such as continuous atrial pacing could reduce the need for high
rate pacing and avoid slow heart rates (19). Such devices could
eliminate the Y-connector requirement by reconfiguring the
header to allow three ports and avoid additional hardware and
its problems.
Mechanism of AF prevention and remodelling of atrial
myocardium. The mechanism of AF prevention with dual-site
atrial pacing can only be surmised from our data. Continuous
pacing can suppress triggering premature atrial beats as well as
modify the conduction delay and recovery of excitability in
specific atrial regions. Our current studies suggest that prema-
ture atrial beats for spontaneous AF often arise in the crista
terminalis, interatrial septum and superior left atrium (20).
Maximal conduction delay for right atrial premature beats
exists in the septum, His bundle and coronary sinus ostial
regions (18). Initiation of spontaneous AF is often in proximity
to the site of atrial premature contractions. Finally, specific
pacing modes may alter (reduce or exaggerate) conduction
delays in these regions (21). Dual-site right atrial and biatrial
pacing may exert the most favorable effects of many pacing
modes in minimizing delay in these atrial regions (22).
Long-term benefit with elimination of AF recurrences may
be ascribed to continuous electrical modification by overdrive
pacing or atrial electrical remodelling with progressive rhythm
control or both mechanisms. Based on our data, we would
suggest both mechanisms are operative. Individual patients
who were not paced for even brief periods could have AF
recurrence, suggesting the need for continuous electrical sub-
strate modification for effective prevention. Patients with very
frequent or chronic AF without long periods in sinus rhythm
would have all progressed to chronic AF without the possibility
of electrical remodelling. This may in part explain the declining
frequency of AF recurrences after the first six months.
Safety and study limitations. The safety of dual-site right
atrial pacing is established from our data. Complications
observed were conventional for atrial pacing without evidence
of increased problems related to the additional atrial lead.
Coronary sinus lead dislodgement after hospital discharge was
not observed. This is in contrast to distal coronary sinus
placement of pacing and defibrillation leads with reported
rates of 8–20% (23,24). Our study does not establish the
long-term rhythm control for single-site atrial pacing but this is
available in some other reports (7,8). The memory in device
datalogs was limited to eight events and could be saturated by
high density-sensed events. As such, the total AF event rate
could not be accurately assessed.
Conclusions. In this prospective study, atrial pacing in
combination with antiarrhythmic drug therapy can eliminate or
markedly reduce recurrent AF in patients with drug-refractory
AF. While neither right atrial site used had superior efficacy
for single-site pacing, dual-site right atrial pacing had signifi-
cant incremental benefit demonstrable in the crossover study.
Long-term rhythm control is effectively and safely achieved
with rare progression to chronic AF, particularly in paroxysmal
or persistent AF. Infrequent cardioversion may be needed in a
minority of patients for this purpose. Antithrombotic therapy
could be withdrawn in one third of patients without adverse
embolic events in the follow-up period of 2–4 years. Dual-site
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atrial pacing should be an integral element of implantable
arrhythmia management devices for AF incorporating brady-
cardia and antitachycardia pacing, cardioversion and defibril-
lation. Future directions in technology could include elimina-
tion of Y-connectors and availability of continuous atrial
pacing algorithms as well as antitachycardia pacing and defi-
brillation for patients with infrequent AF recurrences in a
given patient.
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